Group 1: Economic Policy and Strategy - The Central Economic Work Conference emphasized the need for a strong domestic market and the expansion of domestic demand as the primary economic task for the upcoming year [2] - The conference highlighted the importance of implementing more proactive fiscal policies and moderately loose monetary policies to enhance the consistency and effectiveness of macroeconomic policies [1][2] - Specific measures proposed include actions to boost consumption, develop new productive forces, and address risks in key areas, with a focus on responding to both domestic and international challenges [1][2] Group 2: Financial Support for Consumption and Innovation - Financial institutions are encouraged to leverage policy tools to support consumption and investment, fostering a positive interaction between supply and demand [2] - The Industrial and Commercial Bank of China reported a record credit issuance of nearly 100 billion yuan in sectors such as culture, tourism, education, and elderly care, reflecting strong financial support for these areas [3] - The conference called for innovation in financial services to support technology-driven enterprises, which are seen as vital for cultivating new economic momentum [4][5] Group 3: Support for Small and Micro Enterprises - The conference's initiatives are expected to benefit small and micro enterprises significantly, with banks urged to increase credit resources for these businesses [7] - The Bank of China emphasized the need for tailored financial services for small and micro enterprises, particularly in foreign trade, technology, and consumption sectors [8] - Specific examples include a Qinghai-based biopharmaceutical company receiving a 2 million yuan loan to address cash flow issues caused by rising logistics costs and exchange rate fluctuations [8]

本报讯 记者冯瑶 通讯员黄倩 游江天报道 近日，中国人民银行河北省分行综合部署、统筹谋划，提前一 个多月完成中化集团财务有限责任公司、中国华能财务有限责任公司涉及金融统计、存款准备金、跨境 人民币、外汇业务等系统数据迁移和业务备案工作，开创了央企迁移的先河，为后续更多迁移提供了宝 贵经验，形成了较强的示范效应。 作为首批疏解金融机构，两家财务公司填补了雄安新区财务公司的机构类型空白，完善了河北省多层 次、广覆盖、差异化的金融机构体系，优化了雄安新区金融生态环境，有力推动河北省的金融业创新发 展。截至目前，河北省法人财务公司增至8家，资产规模是迁移前的1.6倍。同时，两家财务公司落户雄 安新区将更好助力央地合作，有效融合河北省产业发展，构建"国际投资—北京研发—雄安落地—河北 转化"的科创金融链条，推动北京科技成果在河北省产业化转化。 疏解启动前，两家财务公司的金融统计数据均体现在全国金融业增加值中。为真实、准确反映河北省金 融业实际规模，推动两家财务公司的统计归属调整至河北，中国人民银行河北省分行多次向中国人民银 行请示沟通并获得支持。疏解过程中，中国人民银行河北省分行打破"北京撤销—河北新设"的传统模 式， ...

Core Viewpoint - The newly released "Management Measures for Financing Lease Business of Financial Leasing Companies" aims to strengthen compliance and regulate the financing lease business, emphasizing the importance of asset management and risk responsibility in the industry [1][2]. Group 1: Regulatory Framework - The new regulation is part of a series of measures to solidify compliance in the financial leasing industry, following the revised "Management Measures for Financial Leasing Companies" and "Regulatory Rating Measures for Financial Leasing Companies" [1]. - The regulation consists of 68 articles, with a strong focus on risk management and asset compliance, mentioning "risk" 61 times and "leased assets" 73 times throughout the document [1]. Group 2: Responsibilities and Compliance - The regulation clarifies the responsibilities of company leaders, business personnel, risk control staff, and internal audit personnel regarding asset management, highlighting the need for compliance in leasing operations [2]. - Compliance with asset suitability and legality is emphasized, with specific prohibitions against using low-value consumables or assets with ownership disputes as leased items [3]. Group 3: Asset Management - Financial leasing companies are required to ensure that leased assets meet two core criteria: clear ownership and compliance with regulatory standards [4]. - The regulation mandates thorough investigations into the specific conditions of leased assets, including their physical state, delivery status, and operational qualifications [4]. Group 4: Vendor Relationships - When collaborating with manufacturers for financing lease operations, companies must investigate the manufacturers' operational status, market reputation, and financial health [5]. - Companies are advised against blindly trusting dealers and service providers, emphasizing the need for due diligence in vendor relationships [6]. Group 5: Strategic Development - To achieve sustainable development in a competitive market, financial leasing companies must align their operations with national strategies and support high-quality economic development [6]. - The focus should be on enhancing compliance management as a core competitive advantage while maintaining a clear understanding of permissible and impermissible actions within the regulatory framework [6].

Economic Overview - The economic situation in China is stabilizing and improving, with strong momentum for high-quality development, as indicated by tax data released by the State Taxation Administration [1] - Key characteristics of high-quality economic development include a stable economic situation, continuous optimization of economic structure, sustained enhancement of economic momentum, and more standardized economic order [1] Tax Revenue and Business Activity - In the first 11 months, the number of active enterprises increased by 9.8% year-on-year, with tax revenue exceeding 29 trillion yuan, including over 16 trillion yuan in tax revenue (excluding export tax rebates), which is a 3.1% increase year-on-year [2] - Social security fee revenue exceeded 8 trillion yuan, growing by 4.9% year-on-year, while non-tax revenue from land use rights and mineral resources approached 5 trillion yuan, indicating an optimized tax revenue structure [2] Manufacturing Sector - The manufacturing sector remains a stabilizing force, with tax revenue from manufacturing holding steady at around 30% [2] - Sales revenue in the equipment manufacturing sector grew by 8.3%, with significant increases in computer and communication equipment manufacturing (12.3%) and instrument manufacturing (10.3%) [2] - Investment in automation and digital technology by manufacturing enterprises increased by 14.2% and 11.2% respectively, indicating deeper integration of digital technology in manufacturing [2] Energy Sector - Sales revenue in clean energy sectors, including wind, solar, and hydropower, grew by 14.9%, reflecting a rapid transition towards a greener energy structure [3] Innovation and Technology - The role of technological innovation is increasingly significant, with tax incentives for innovation and manufacturing amounting to 237.25 billion yuan in the first 10 months [3] - High-tech industry sales revenue increased by 14.7%, with smart device manufacturing seeing a remarkable growth of 28.2% [3] Traditional Industries - Traditional industries are investing more in R&D, with a 12.3% increase in R&D spending among key tax source enterprises in the first three quarters [4] - There is a notable increase in the procurement of digital and automated equipment, with growth rates of 7.6% and 9.3% respectively, and a significant 33.2% increase in energy-saving and environmental protection technology services [4] Consumer Market Trends - The consumption market is showing positive changes, with sales in the communication equipment and home appliance sectors growing by 20.3% and 26.5% respectively [4] - The "event economy" is driving consumption, with sports and health sectors experiencing significant growth, including a 29.7% increase in sports exhibition services [5] - The elderly population's consumption needs are rising, with a 33.6% increase in spending on elderly care services [5]

Core Viewpoint - The Central Economic Work Conference emphasizes the need to address both old problems and new challenges in China's economy while maintaining confidence in long-term growth prospects [1][2]. Economic Policy Direction - The conference sets a tone of "steadfast confidence, leveraging advantages, and responding to challenges" for economic work in the coming year [1]. - The focus will be on "stabilizing while seeking progress and improving quality and efficiency" in policy formulation, indicating a shift from short-term stimulus to long-term development planning [1][2]. Incremental and Stock Policy - The meeting highlights the importance of "optimizing increment and revitalizing stock," indicating a systematic restructuring towards higher efficiency and sustainability in policy, industry, and investment [3][4]. - Specific areas of focus include real estate, fiscal policy, and investment, with strategies such as "city-specific policies to control increment, reduce inventory, and optimize supply" [3][4]. Monetary Policy - The monetary policy will continue to adopt a moderately loose stance, with a focus on stabilizing economic growth and ensuring reasonable price recovery [5][6]. - The emphasis will be on enhancing the effectiveness of monetary policy through structural tools while maintaining a balance between increment and stock [5][7]. Fiscal Policy - The fiscal policy will reflect the principles of optimizing increment and implementing stock, with higher demands for fiscal discipline and spending efficiency [8][9]. - Predictions indicate that the fiscal deficit rate will remain around 4%, with an increase in special bond quotas and a shift in spending towards social welfare, education, and technology [8][9].

Core Viewpoint - The launch of the "CFETS-SHCH-CBR Sci-Tech CDS Index" aims to enhance the interbank credit derivatives market, diversify product offerings, and support the development of the bond market's "Sci-Tech Board" [1] Group 1: Index Composition and Structure - The Sci-Tech CDS Index consists of 25 prominent issuers in the sci-tech bond market, focusing on sectors such as new-generation information technology, biotechnology, new energy, new materials, high-end equipment, new energy vehicles, green environmental protection, aerospace, and marine equipment [2] - Each constituent entity in the index, including companies like BYD, Geely Holding, and China Electronics, has an equal weight of 4% [2] Group 2: Functionality and Benefits - The Sci-Tech CDS Index serves as a trading vehicle, with the trading center providing services and the Shanghai Clearing House conducting bilateral clearing, using China Bond Rating's evaluations as a key reference for risk management [3] - It meets the secondary market trading needs for institutional credit risk management, allowing market makers and investment institutions to hedge against credit risks and credit spread volatility in a basket of sci-tech enterprises [3] - The index trading can enhance the quality and efficiency of financing tools for sci-tech enterprises, helping to release capital and broaden financing channels through a transmission mechanism between primary and secondary markets [3] - Approximately 20 market institutions provide daily bilateral quotes for the CDS index, with the trading center and Shanghai Clearing House compiling and publishing the index credit curve daily, serving as a pricing reference for sci-tech bonds [3] Group 3: Market Development Context - In 2021, the trading association issued guidelines for the compilation and trading of CDS indices, establishing a basic framework for CDS index operations [4] - Currently, there are four CDS index products in the interbank market, including the high-grade CDS index, private enterprise CDS index, Yangtze River Delta CDS index, and the newly launched Sci-Tech CDS index, which enrich the credit risk management tools available to market participants [4]

中国式现代化建设的壮阔征程上，众多坚守初心的企业正以实干笔触描绘高质量发展的鲜活答卷。 其中，国网国际融资租赁有限公司（以下简称"国网租赁"）以实干为基、以创新为翼，为能源电力产业 升级和经济社会高质量发展注入源源不断的金融动能。 来时路，是矢志不渝的奋进之路。作为国家电网有限公司全资子公司，国网租赁坚持"根植主业、 服务实业、以融强产、创造价值"的发展定位，紧紧围绕电网主业和能源电力产业链加快高质量发展步 伐，用创新实践和具体成效给出答案。 时代浪潮滚滚向前，发展蓝图催人奋进。中国共产党第二十届中央委员会第四次全体会议系统擘画 了"十五五"时期我国经济社会发展的宏伟蓝图，为融资租赁企业服务国家战略、推动高质量发展提供了 根本遵循和行动指南。 未来路，是勇毅前行的开拓之路。立足"十四五"圆满收官的坚实基础，国网租赁以党的二十届四中 全会精神为指引，科学谋划"十五五"发展新篇。回望过去，公司为国家电网公司和能源电力行业高质量 发展作出了积极贡献，未来也将以实际行动在实体经济服务、做好"金融五篇大文章"中体现责任与担 当。 锚定"双碳"战略 以创新金融服务构建新型能源体系 渤海之滨，沧州临港经济技术开发区内，16 ...

Core Insights - The 2025 National Medical Insurance Drug List has successfully added 114 new drugs, including 50 innovative drugs, achieving an overall success rate of 88%, significantly higher than the 76% in 2024 [1] - The first version of the Commercial Health Insurance Innovative Drug List has been released, marking a substantial breakthrough in the multi-tiered medical security system [1] - Nine innovative drugs from the Sci-Tech Innovation Board have been included in the new lists, showcasing the strength of these companies [1] Group 1: National Medical Insurance and Commercial Insurance - The new drug lists aim to establish a multi-tiered medical security system, with the basic insurance list covering essential drugs and the commercial insurance list focusing on high-value drugs not covered by basic insurance [4] - Since 2018, 149 innovative drugs have been included in the medical insurance list, accounting for 17% of the new drugs, supported by various policies to facilitate the entry of innovative drugs [2] - The successful inclusion of innovative drugs in the insurance lists reflects the government's recognition of their clinical value and the importance of supporting local innovation [6] Group 2: Sci-Tech Innovation Board Companies - Nearly 90% of the Sci-Tech Innovation Board's biopharmaceutical companies have received medical insurance support for their approved new drugs [2] - Notable products such as Junshi Biosciences' innovative drug, which is the only domestic PCSK9-targeted drug for statin-intolerant patients, have been included in the insurance list [2] - The successful renewal of contracts for drugs like Baiyue's Bai Ze An and Junshi's Tuoyi further expands the insurance coverage, benefiting a wider patient population [6] Group 3: Research and Development Investment - The R&D investment of Sci-Tech Innovation Board companies reached a new high in the first three quarters of 2025, with a year-on-year increase of over 10% and an R&D intensity of 42%, significantly surpassing the overall level of A-shares [6] - Companies like Baiyue have invested over 10 billion yuan in R&D, demonstrating a strong commitment to innovation [6] - The cycle of R&D investment leading to innovative outcomes, insurance support, market returns, and reinvestment in R&D has been established and is continuously strengthening [7]

Core Viewpoint - The Central Economic Work Conference held from December 10 to 11 in Beijing outlined key tasks for economic work in 2026, emphasizing the need for policy support and reform innovation to address current economic challenges [2][3]. Group 1: Economic Policy Direction - The conference highlighted five essential approaches for economic work under the new circumstances, including fully tapping economic potential and ensuring a balance between policy support and reform innovation [3]. - Emphasis was placed on maintaining a stable yet progressive approach to economic governance, integrating existing and new policies for effective outcomes [4]. Group 2: Fiscal and Monetary Policy - The conference called for increased counter-cyclical and cross-cyclical adjustments to enhance macroeconomic governance effectiveness, alongside a more proactive fiscal policy [5]. - It was noted that maintaining necessary fiscal deficits and total debt levels while optimizing fiscal expenditure structures is crucial for addressing local fiscal difficulties [5]. - A moderately loose monetary policy will continue, focusing on stabilizing economic growth and ensuring reasonable price recovery [5][6]. Group 3: Key Economic Tasks for 2026 - Eight key tasks for economic work in 2026 were identified, including: 1. Fostering a strong domestic market driven by internal demand [8]. 2. Accelerating innovation to cultivate new growth drivers [8]. 3. Enhancing quality development through reform efforts [8]. 4. Promoting multi-field cooperation and openness [8]. 5. Encouraging coordinated development for urban-rural integration and regional synergy [8]. 6. Leading with "dual carbon" initiatives for comprehensive green transformation [8]. 7. Prioritizing people's livelihoods by addressing practical issues for the public [8]. 8. Safeguarding against risks in key areas through proactive and prudent measures [8].

Core Insights - The release of the 2025 National Medical Insurance Drug List and the first version of the Commercial Health Insurance Innovative Drug List has significantly benefited innovative drug companies on the Sci-Tech Innovation Board [1] - A total of 9 innovative drugs from Sci-Tech Innovation Board companies have been included in the new list, showcasing their strong capabilities [1] - The simultaneous release of the commercial insurance drug list marks a substantial breakthrough in the multi-layered payment system of "medical insurance + commercial insurance" [1] Group 1: Inclusion in Medical Insurance - Nearly 90% of innovative drugs from Sci-Tech Innovation Board companies have received medical insurance support, accelerating their value release and development [2] - Junshi Bioscience's drug, Junsida, is the only domestic PCSK9-targeted drug for statin-intolerant patients included in the new medical insurance list [2] - Haichuang Pharmaceutical's drug, Hainaan, has been approved for treating metastatic castration-resistant prostate cancer and will enhance market promotion and patient accessibility [2] Group 2: New Drug Development - New anti-tumor drugs from companies like Ailis, Yifang Biotech, and Shenzhou Cell provide precise treatment options for major diseases such as lung cancer and head and neck squamous cell carcinoma [3] - Several drugs covering endocrine, hematology, tumor support, and autoimmune treatment areas have been quickly included in the medical insurance list, demonstrating efficient drug review and approval processes [3] Group 3: Commercial Health Insurance Directory - The first version of the Commercial Health Insurance Innovative Drug List enhances the national multi-layered medical security system, with a clear division of roles between basic medical insurance and commercial insurance [4] - Innovative drugs from leading companies like BeiGene have been among the first to be included in this new directory, showcasing their clinical value [4][5] Group 4: Renewal and Market Expansion - Successful renewal negotiations confirm the exceptional value and clinical status of innovative drugs from Sci-Tech Innovation Board companies [6] - Junshi Bioscience's drug, Tuoyi, has expanded its medical insurance coverage with new indications, benefiting a broader patient population [6] Group 5: R&D Investment and Innovation Cycle - R&D investment among Sci-Tech Innovation Board companies reached a new high in the first three quarters of 2025, with a year-on-year increase of over 10% and an R&D intensity of 42% [7] - The formation of a virtuous cycle of "R&D investment - innovation results - medical/commercial insurance support - market returns - reinvestment in R&D" is evident in the industry [7]